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Abstract BACKGROUND CONTEXT: Patients with large annular defects after lumbar discectomy for disc
herniation are at high risk of symptomatic recurrence and reoperation.
PURPOSE: The present study aimed to determine whether a bone-anchored annular closure device,
in addition to lumbar microdiscectomy, resulted in lower reherniation and reoperation rates plus in-
creased overall success compared with lumbar microdiscectomy alone.
DESIGN: This is a multicenter, randomized superiority study.
PATIENT SAMPLE: Patients with symptoms of lumbar disc herniation for at least 6 weeks
with a large annular defect (6–10 mm width) after lumbar microdiscectomy were included in the
study.
OUTCOME MEASURES: The co-primary end points determined a priori were recurrent hernia-
tion and a composite end point consisting of patient-reported, radiographic, and clinical outcomes.
Study success required superiority of annular closure on both end points at 2-year follow-up.
METHODS: Patients received lumbar microdiscectomy with additional bone-anchored annular closure
device (n=276 participants) or lumbar microdiscectomy only (control; n=278 participants). This re-
search was supported by Intrinsic Therapeutics. Two authors received study-specific support more
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1529-9430/© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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than $10,000 per year, 8 authors received study-specific support less than $10,000 per year, and 11
authors received no study-specific support.
RESULTS: Among 554 randomized participants, 550 (annular closure device: n=272; control: n=278)
were included in the modified intent-to-treat efficacy analysis and 550 (annular closure device: n=267;
control: n=283) were included in the as-treated safety analysis. Both co-primary end points of the
study were met, with recurrent herniation (50% vs. 70%, P<.001) and composite end point success
(27% vs. 18%, P=.02) favoring annular closure device. The frequency of symptomatic reherniation
was lower with annular closure device (12% vs. 25%, P<.001). There were 29 reoperations in 24
patients in the annular closure device group and 61 reoperations in 45 control patients. The frequen-
cy of reoperations to address recurrent herniation was 5% with annular closure device and 13% in
controls (P=.001). End plate changes were more prevalent in the annular closure device group (84%
vs. 30%, P<.001). Scores for back pain, leg pain, Oswestry Disability Index, and health-related quality
of life at regular visits were comparable between groups over 2-year follow-up.
CONCLUSIONS: In patients at high risk of herniation recurrence after lumbar microdiscectomy,
annular closure with a bone-anchored implant lowers the risk of symptomatic recurrence and reoperation.
Additional study to determine outcomes beyond 2 years with a bone-anchored annular closure device
is warranted. © 2018 The Authors. Published by Elsevier Inc. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Annular closure; Disc herniation; Lumbar discectomy; Randomized controlled trial; Recurrent herniation;
Sciatica
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Introduction
Sciatica is characterized by radiating buttock and leg pain
in a lumbar nerve root distribution, which may be accompa-
nied by sensory and motor deficits. The annual incidence of
an episode of sciatica in the general population ranges from
1% to 5% [1]. The most common cause of sciatica is inter-
vertebral disc herniation. Initial treatment of sciatica is
conservative given the favorable natural history in most pa-
tients. In approximately 20% of patients, symptoms may persist
despite conservative management [2,3]. These patients may
continue conservative treatment or undergo surgical removal
of herniated disc material, with surgery resulting in faster
symptom relief [4]. However, recurrent symptomatic disc her-
niation occurs in 7%–18% of patients within 2 years after
surgery [5–7]. Recurrent symptomatic herniation is associ-
ated with poor clinical outcome and requires a technically
demanding, expensive reoperation in most cases [6,8].
With almost half a million discectomies performed in
the United States per year [9], this poses a significant
problem not only for the affected individuals but also for
society overall.
As the annulus fibrosus has limited healing capacity, a
large annular defect after microdiscectomy is a major risk
factor for herniation recurrence. Carragee et al. [10] re-
ported symptomatic herniation recurrence rates of 27% in
defects larger than 6 mm, but only 1% in small annular
fissures. Thus, the clinical burden of herniation recurrence
after microdiscectomy may be mitigated by development of
treatments that reliably occlude large annular defects. A
bone-anchored annular closure device (ACD) has shown
promising results in single-arm studies to address recurrent
herniation after lumbar microdiscectomy [11,12]. The aim
of this randomized controlled trial was to determine whether
bone-anchored ACD, in addition to lumbar microdiscectomy,
resulted in lower reherniation and reoperation rates plus
increased overall success.
Methods
Trial design and oversight
We conducted a multicenter randomized controlled
trial in patients who were operated on for sciatica caused
by lumbar disc herniation and who had a large annular
defect after lumbar discectomy. The primary objective of
this trial was to determine whether implantation of
a bone-anchored ACD after lumbar discectomy reduced the
risk of recurrent herniation compared with lumbar discectomy
alone. The clinical trial was approved by the local ethics
committees, and all participants provided written informed
consent. This study was prospectively registered at
ClinicalTrials.gov (NCT01283438). Details of the study
rationale, design, and methods have been described previ-
ously [13].
The authors designed the trial in collaboration with the
Food and Drug Administration. The study was sponsored
by Intrinsic Therapeutics, which manufactures the
ACD and was involved in trial management and data
monitoring. Two authors received study-specific support
of more than $10,000 per year, 8 authors received
study-specific support less than $10,000 per year, and 11
authors received no study-specific support. No authors, in-
vestigators, or site staff have any equity, royalty, or
other financial interest in either Intrinsic Therapeutics or
the Barricaid device. Data were analyzed by an indepen-
dent statistician, and radiographic assessments were
performed by an independent core laboratory blinded to
patient outcomes. All authors had full access to the data
and the data analysis.
Participants
At 21 European hospitals, we enrolled patients 21–75
years of age, with imaging confirmation of single-level disc
herniation between L1 and S1, with disc height≥5 mm, and
who failed≥6 weeks of nonsurgical treatment. Magnetic
resonance imaging (MRI) with T1- and T2-weighted axial
and sagittal images, low-dose, multiplanar computed
tomography (CT), and flexion-extension x-rays were per-
formed. All patients had lumbar radiculopathy with positive
straight leg raise or femoral stretch test, and Oswestry Dis-
ability Index score (ODI) and visual analog scale (VAS) leg
pain score of at least 40/100 on each. Patients with spondy-
lolisthesis (Grade II or higher), previous surgery at the index
level, or osteoporosis were excluded. Additional informa-
tion on the inclusion and exclusion criteria are provided in
Supplementary Table S1.
Interventions
Experienced spinal surgeons had performed at least
three cases with ACD implantation before enrolling pa-
tients in this study. With patients under general anesthesia
in most cases, magnification-assisted limited discectomy
was performed via an interlaminar transflaval approach
[14]. After completion of the discectomy, the annular defect
was measured with sizing probes provided in an accessory
kit, and the final inclusion criterion was applied. If the
annular defect was 4–6 mm tall and 6–10 mm wide, the
patient qualified for randomization and no additional disc
material was removed. This range of annular defect sizes
was chosen to identify patients at high risk of recurrence
that could also be treated within the range of available
device sizes. In patients allocated to the control group, the
procedure was concluded by standard incision closure.
Patients allocated to ACD received bone-anchored annular
closure under fluoroscopic guidance. The ACD is com-
posed of a flexible polymer mesh to close the annular
defect and a titanium anchor to secure the mesh to an
adjacent vertebral body (Supplementary Fig. S1). The tita-
nium anchor does not interfere with MRI interpretation or
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the ability to detect reherniation. Postoperative care was
provided according to the protocols of the participating
surgical departments.
Follow-up and outcomes
Patients returned for follow-up visits at 6 weeks, 3 months,
6 months, 1 year, and 2 years. Computed tomography, MRI,
and flexion-extension x-rays were performed at 1 and 2
years (Supplementary Table S2). Outcomes of this trial
were measured using patient-reported data obtained from
questionnaires, independent imaging assessment, and inves-
tigator reports of adverse events and reoperations. Patient-
reported outcomes included ODI for back-related disability
(0–100 scale) [15], VAS (0–100 scale) for back and leg
pain [16], and health-related quality of life with the Medical
Outcomes Study 36-Item Short-Form General Health Survey
(SF-36) scale [17].
The trial included two co-primary end points. Study success
required that outcomes with ACD were statistically superi-
or to controls for both end points. One primary end point
was incidence of recurrent herniation through 2 years. Re-
current herniation was confirmed during reoperation or by
identification of protrusion, extrusion, or sequestration at
any location of the index-level disc on imaging by indepen-
dent radiologists [18]. The other primary end point was a
composite consisting of (1) ≥15-point improvement in ODI
compared with baseline; (2) ≥20-point improvement in leg
pain VAS compared with baseline; (3) maintenance of ≥75%
disc height compared with baseline; (4) maintenance of
device condition and neurologic status; and (5) freedom
from index level reherniation, index level reoperation, and
spontaneous fusion. Given that each primary end point com-
prised imaging findings even if no clinical symptoms were
present, a post hoc modified composite end point was de-
veloped that included only symptomatic outcomes and was
considered more clinically meaningful. This modified com-
posite end point consisted of (1) freedom from symptomatic
recurrent herniation, (2) ≥15-point improvement in ODI
compared with baseline, (3) ≥20-point improvement leg
pain VAS compared with baseline, (4) maintenance of neu-
rologic status, (5) freedom from device- or procedure-
related serious adverse event, and (6) freedom from index
level reoperation.
Symptomatic herniation recurrence included recurrent
herniation that was either surgically verified during reoperation,
identified by the imaging core laboratory where the patient
reported at least moderate (40/100) disability, radicular
symptoms, and neurologic deterioration, or reported as an
adverse event. The decision to reoperate during follow-up
was collectively made by one of the investigators and the
patient based on imaging findings, patient-reported
symptoms, and patient preferences. The occurrence of
adverse events was ascertained at each study contact and
routinely monitored for accuracy. An independent data
safety monitoring board (DSMB) adjudicated adverse events
by seriousness and by relatedness to the procedure or
implant.
Randomization and blinding
After lumbar discectomy and intraoperative confirma-
tion of eligible defect measurements, patients were randomly
allocated in a 1:1 ratio, with a block size of four, to receive
additional ACD or discectomy alone. Simple randomiza-
tion was performed intraoperatively with a central web-
based system that enabled real-time computer-generated
random treatment assignment. Neither surgeons nor pa-
tients were blinded to the treatment group except for patients
in the Netherlands who were blinded to the treatment group
because of regional allowances.
Statistical analysis
A Bayesian approach to sample size selection was used
[19]. Interim analyses were performed after enrollment of 400
patients and repeated at increments of 50 patients thereafter
until the predictive probability of trial success on each primary
end point exceeded 90% or the maximum sample size of 800
patients was reached. Efficacy analyses were performed on
a modified intention-to-treat (ITT) population, which in-
cluded all randomized patients in whom the intended procedure
was attempted. Safety analyses were performed on an
as-treated population. An ITT (as randomized) population was
included as a sensitivity analysis. Baseline patient charac-
teristics are presented as means and standard deviations for
continuous variables and numbers and percentages for cat-
egorical variables. Outcomes between the groups were assessed
with Student t test for continuous data or Fisher exact test
for categorical data. Time-to-event data were analyzed using
Kaplan-Meier methods with log-rank tests for group com-
parisons. Statistical significance was set at P<.05 and
hypothesis testing was two-sided. Statistical analyses were
performed using SAS v9.4 (SAS Institute, Cary, NC, USA)
and R v3.3.2 (R Foundation for Statistical Computing, Vienna,
Austria).
Results
Between December 2010 and October 2014, 554 pa-
tients were randomly allocated to ACD (n=276) or control
(n=278). A list of participating centers is reported in
Supplementary Table S3. In four patients allocated to ACD,
implantation was not attempted owing to proximity of the nerve
root to the planned implant location. Therefore, the modi-
fied ITT population included 550 patients (272 ACD, 278
controls). Implantation of the ACD was unsuccessful in five
patients, including four patients in whom the mesh did not
fully enter the disc and one patient with nerve root injury
during attempted implantation; thus, the as-treated popula-
tion included 267 patients in the ACD group and 283 controls.
Compliance with clinical follow-up at 2 years was 91% in
each group (Fig. 1).
2281C. Thomé et al. / The Spine Journal 18 (2018) 2278–2287
Treatment groups were well matched at baseline (Table 1).
The mean age of the study population was 43 years, and 59%
were men, which is consistent with findings in previous reports
of patients undergoing lumbar microdiscectomy [4,20]. The
mean volume of nucleus removal was 1.3 mL in each group;
surgery duration (70 minutes vs. 52 minutes, P<.001) and pro-
cedural blood loss (98 cc vs. 67 cc, P<.01) were higher with
ACD versus controls.
Herniation recurrence, diagnosed based on imaging or
symptoms, was identified in 50% of patients in the ACD
group and in 70% of controls at 2 years (mean difference:
−20%, 95% confidence interval [CI]: −12% to −28%, P<.001)
(Table 2). Clinical success on the primary composite end
point was 27% with ACD and 18% with controls (mean
difference: 9%, 95% CI: 2%–16%, P=.02). Thus, both co-
primary end points of the study were met. Outcomes of the
modified composite end point yielded similar conclusions,
with 76% success in the ACD group and 66% in controls
(mean difference: 10%, 95% CI: 2%–18%, P<.02)
(Supplementary Table S4).
The frequency of symptomatic reherniation was lower with
ACD (12% vs. 25%, P<.001) (Fig. 2). Mean leg pain sever-
ity decreased by 84%, on average, at the regular visits over
2 years with no difference between groups (Supplementary
Fig. S2). Back pain severity decreased by 66%, on average,
at the regular visits through 2 years with no difference between
groups (Supplementary Fig. S3). At 2 years, mean ODI scores
were comparable (Supplementary Fig. S4). Health-related
quality of life significantly improved with no differences ob-
served between groups. Physical component summary scores
increased from 29±6 to 49±9 with ACD and 29±6 to 47±9
in controls (Supplementary Fig. S5). Mental component
summary scores increased from 40±13 to 52±10 with ACD
and 41±13 to 51±11 in controls (Supplementary Fig. S6).
Index level reoperations were less frequent with ACD
(9% vs. 16%, P=.01). There were 29 reoperations in 24
ACD patients and 61 reoperations in 45 control patients
(Fig. 3). The frequency of index level reoperations specifi-
cally to address an observed recurrent herniation was 5%
with ACD (14 procedures in 14 subjects) and 13% in con-
trols (42 procedures in 37 subjects) (P<.001). Of the 14
reoperations for recurrence in the ACD group, 3 were also
associated with detachment of the mesh portion of the device
from the anchor and the fourth one was associated with a
fracture of anchor head; in each of these cases, the de-
tached portion was removed and the rest remained implanted.
In the as-treated population, the frequency of serious adverse
events adjudicated by the DSMB as related to either the
implant or procedure was 7% in the ACD group and 17% in
the control group (P=.001); this difference was primarily
due to the lower incidence of reherniation in the ACD
group. No difference in all-cause serious adverse events
was observed when comparing ACD with controls (25% vs.
30%, P=.15). The frequency of adverse events, regardless
of seriousness or relatedness, was 75% with ACD and 70%
in controls (P=.29). Serious device- and procedure-related
serious adverse events in the modified ITT population are
reported in Table 3. Detailed listings of serious adverse
events, serious device- and procedure-related adverse events,
and adverse events regardless of seriousness or relatedness
are reported in Supplementary Tables S5–S7 for the as-
treated population and Supplementary Tables S8–S9 for the
modified ITT population.
Assessment of all available CT images by the indepen-
dent radiographic core laboratory identified end plate changes
(disruptions in the smooth cortical margin of the bony end
plate) after surgery with and without the ACD. Changes were
more prevalent in the ACD group at 2 years (84% vs. 30%,
P<.001), although no correlation with any symptom or clin-
ically adverse event was observed.
A sensitivity analysis of main study outcomes in an ITT
population did not alter study conclusions (Supplementary
Table S10).
Table 1







Male sex—no. (%) 156 (57) 171 (62)
Body mass index—kg/m2 26±4 26±4
Smoking history—no. (%) 173 (64) 175 (63)
Medical history—no. (%) †
Musculoskeletal 95 (35)‡ 91 (33)§
Head and neck 62 (23)‡ 54 (20)§
Gastrointestinal 53 (20)ǁ 59 (21)‡
Cardiovascular 49 (18)‡ 48 (17)‡
Genitourinary 39 (14)‡ 35 (13)‡
Skin 29 (11)‡ 30 (11)‡
Respiratory 28 (10)‡ 44 (16)‡
Visual analog scale for leg pain¶ 81±15 81±15
Visual analog scale for back pain¶ 57±30 56±31
Oswestry Disability Index score# 59±12 58±14
SF-36 Physical Component Summary score** 29±6 29±6
SF-36 Mental Component Summary score** 40±13 41±13
Index level—no. (%)
L2-L3 2 (1) 1 (<1)
L3-L4 8 (3) 5 (2)
L4-L5 123 (45) 101 (36)
L5-S1 139 (51) 171 (62)
Spondylolisthesis, Grade 1 6 (2) 8 (3)
Disc height—mm 8.9±2.1 8.9±2.2
Extrusion/Sequestration—no. (%) 201 (74) 201 (72)
* Plus-minus values are mean±SD.
† Medical history variables reported with frequency of 10% or more in
either group.
‡ Data from two patients not reported.
§ Data from one patient not reported.
ǁ Data from three patients not reported.
¶ Scores on the visual analog scale (VAS) range from 0 to 100, with
higher scores indicating more severe pain.
# Scores on the Oswestry Disability Index (ODI) range from 0 to 100,
with higher scores indicating more severe disability.
** Physical Component Summary and Mental Component Summary scores
from the Medical Outcomes Study 36-Item Short-Form General Health Survey
(SF-36) scale range from 0 to 100, with higher scores indicating better health-
related quality of life.
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Discussion
This multicenter randomized controlled trial demon-
strated that additional use of a bone-anchored ACD after
lumbar microdiscectomy reduced the risk of symptomatic re-
currence and associated reoperations. The number needed to
treat to prevent a reherniation was less than 8 and to prevent
an associated reoperation was less than 13. Further, these ben-
efits were not offset by a higher risk of adverse events. Given
that lumbar discectomy is the most frequently performed spine
surgery in the United States with close to half a million
procedures each year [9], the findings of this study have sig-
nificant societal importance, as reoperations are known to be
associated with poor outcome and extensive additional
costs [6,8].
The results of this study are generalizable to patients with
large annular defects after lumbar microdiscectomy.
Fig. 1. Enrollment and randomization of patients. Intent-to-treat (ITT) population consisted of 276 patients assigned to anular closure device (ACD) group
and 278 patients assigned to control group. Modified ITT population consisted of 272 patients with attempted ACD implant and 278 patients assigned to
control group. As-treated population consisted of modified ITT population where 267 patients received ACD and 283 received control. In the as-treated pop-
ulation, failed ACD implantation in five ACD patients from the modified ITT population (including one with nerve root injury) resulted in assignment to the
control group. Compliance with clinical follow-up at 2 years was 91% in each group.
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Although the symptomatic recurrence rate of 25% in the
control group was markedly higher than the 7%–18% recur-
rence rates frequently reported after discectomy [5–7], this
was an anticipated result given the large annular defect in-
clusion criterion. McGirt et al. [7] reported that recurrence
rates were four times higher in patients in the top quartile of
annular defect size versus those in the lower quartile. In pa-
tients with annular defect size≥6 mm, recurrence rates through
2-year follow-up were 18% in the study of Kim et al. [21]
and 27% in the study of Carragee et al. [10]. These findings
have been corroborated in a meta-analysis that reported the
risk of reherniation and reoperation after limited lumbar
discectomy was approximately threefold higher in patients
with large versus small annular defects [22].
The co-primary end points of the study must be inter-
preted within the context of a sample at high risk of recurrence,
as well as considering that the threshold for defining recur-
rence was stringent. The definition of reherniation included
imaging evidence of protrusion, extrusion, or sequestration,
even in asymptomatic patients. Indeed, the majority of re-
current disc herniations were classified as protrusions in
asymptomatic patients. Although both co-primary end points
of the trial were met, each end point included information
that was derived from imaging assessments. The clinical
relevance of these end points is debatable given the known
lack of association between MRI findings and symptoms in
this population [23,24]. Given the inherent challenges with
interpretation of the primary end points based on the
asymptomatic reherniation rate of 42% in the entire
sample, a post hoc modified composite end point was devel-
oped that was considered to be more clinically meaningful
and demonstrated an increase of the success rate by 10%
with ACD (76% vs. 66% in controls). Overall, additional
ACD implantation reduced the risk of clinically important
Table 2
Main outcomes at 2 years*
Characteristic Annular closure Control p-Value
Index level recurrent herniation—no. (%)†
Symptomatic 31/250 (12) 65/257 (25) <.001
Symptomatic and asymptomatic 125/250 (50) 180/257 (70) <.001
Index level reoperation—no. (%)‡
Recurrent herniation 14/272 (5) 37/278 (13) .001
Any cause 24/272 (9) 45/278 (16) .01
Neurologic function decline—no. (%)§ 5/252 (2) 12/251 (5) .09
Visual analog scale for leg painǁ,¶ 12±21‡‡ 14±21‡‡ .32
Visual analog scale for back painǁ,¶ 18±23‡‡ 19±24‡‡ .54
Oswestry Disability Index scoreǁ,# 13±14‡‡ 14±15‡‡ .27
SF-36 Physical Component Summary scoreǁ,** 49±9‡‡ 47±9‡‡ .07
SF-36 Mental Component Summary scoreǁ,** 52±10‡‡ 51±11‡‡ .23
Serious adverse event—no. (%)††
Device- or procedure-related 19/267 (7)§§ 47/283 (17) .001
Any cause 66/267 (25) 86/283 (30) .15
* Plus-minus values are mean±SD.
† Denominator includes patients in the modified intent-to-treat population with imaging at 2 years and patients with recurrent herniation at any time during
follow-up.
‡ Denominator includes all patients in the modified intent-to-treat population.
§ Denominator includes all patients in the modified intent-to-treat population with data at baseline and 2 years.
ǁ Denominator includes all patients in the modified intent-to-treat population with data at 2 years.
¶ Scores on the visual analog scale (VAS) range from 0 to 100, with higher scores indicating more severe pain.
# Scores on the Oswestry Disability Index (ODI) range from 0 to 100, with higher scores indicating more severe disability.
** Physical Component Summary and Mental Component Summary scores from the Medical Outcomes Study 36-Item Short-Form General Health Survey
(SF-36) scale range from 0 to 100, with higher scores indicating better health-related quality of life.
†† Denominator includes all patients in the as-treated population.
‡‡ N=252.
§§ N=8 subjects experienced a device-related SAE.
Fig. 2. Freedom from symptomatic index level reherniation through 2 years.
Kaplan-Meier freedom from event estimates in the modified intent-to-treat
population through the end of the 2-year follow-up interval (Day 790) were
88.3% for annular closure device (ACD) and 75.6% for control (log-rank
p-value<.001).
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outcomes such as symptomatic herniation recurrence and
reoperation, which are arguably the most important find-
ings of this study.
Prevention of recurrent symptomatic herniation is a
clinically meaningful pursuit as repeat discectomy is tech-
nically demanding and considerably more expensive compared
with primary discectomy [25]. Several strategies to repair,
replace, or regenerate the herniated nucleus pulposus have
been evaluated yet none have resulted in a clinically proven
therapy as the damaged annulus fibrosus had been largely
ignored [26,27]. The annulus fibrosus has limited regenera-
tive capacity, which is likely because exterior repairs are
not matched to the demands of intradiscal tensile forces
[26]. Efforts to develop a definitive annular repair mecha-
nism to date have been unsuccessful. The implant that was
evaluated in the present study is anchored into the adjacent
vertebral body, which may provide a more durable repair.
On balance, some clinical considerations with the ACD
include longer procedure time and potential for device-
related problems. As previously demonstrated after ACD
Fig. 3. Freedom from index level reoperation through 2 years. (Left) Kaplan-Meier freedom from index level reoperation for any reason estimates in the
modified intent-to-treat population through the end of the 2-year follow-up interval (Day 790) were 91.0% for annular closure device (ACD) and 83.4% for
control (log-rank p-value<.01). (Right) Kaplan-Meier freedom from index level reoperation for symptomatic reherniation estimates in the modified intent-
to-treat population through the end of the 2-year follow-up interval (Day 790) were 94.7% for ACD and 86.2% for control (log-rank p-value<.001).
Table 3
Serious device- and procedure-related adverse events through 2 years: modified intent-to-treat population
Event
Annular closure (n=272) Control (n=278) Significance
Events Patients % Events Patients % Diff p-Value
Any serious device- or procedure-related adverse event 29 21 7.7% 56 45 16.2% −8.5% .002
Cardiac and vascular 0 0 0.0% 3 3 1.1% −1.1% .25
Bleeding 0 0 0.0% 1 1 0.4% −0.4%
Other 0 0 0.0% 2 2 0.7% −0.7%
Device deficiency 7 7 2.6%
Device deficiency—anchor (whole device) migration 3 3 1.1%
Device deficiency—mesh migration—extradiscal 4 4 1.5%
Disc herniation 13 11 4.8% 43 38 15.5% −10.7% <.001
Herniation—index level 11 9 4.0% 43 38 15.5% −11.4%
Residual herniation—index level 2 2 0.7% 0 0 0.0% 0.7%
Musculoskeletal—lumbar 1 1 0.4% 0 0 0.0% 0.4% .50
Other 1 1 0.4% 0 0 0.0% 0.4%
Neuro—lumbar and lower extremity 1 1 0.4% 0 0 0.0% 0.4% .50
Nerve or spinal root injury: index surgery 1 1 0.4% 0 0 0.0% 0.4%
Pain—lumbar and lower extremity 4 4 1.5% 2 2 0.7% 0.8% .45
Lower extremity only 2 2 0.7% 2 2 0.7% 0.0%
Lumbar 1 1 0.4% 0 0 0.0% 0.4%
Lumbar and lower extremity 1 1 0.4% 0 0 0.0% 0.4%
Wound issue—secondary surgical intervention at index level 3 3 1.1% 8 6 2.9% −1.8% .50
Dural injury/tear or cerebrospinal fluid leak 1 1 0.4% 1 1 0.4% 0.0%
Infection 1 1 0.4% 3 2 1.1% −0.7%
Hematoma 0 0 0.0% 1 1 0.4% −0.4%
Delayed wound healing 1 1 0.4% 0 0 0.0% 0.4%
Dehiscence 0 0 0.0% 1 1 0.4% −0.4%
Deep 0 0 0.0% 2 2 0.7% −0.7%
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implantation, focal areas of bone resorption at the end plates
were noted more frequently in the ACD group, but there
was no relationship of these radiological findings with clin-
ical parameters [26].
Our study had several strengths including effective ran-
domization, high follow-up rates, a sample size representing
one of the largest studies in spine surgery, oversight provid-
ed by a DSMB, and study design collaboration with the Food
and Drug Administration. There are also several important
limitations of this research. The results of this trial are not
generalizable to all patients undergoing lumbar discectomy
for disc herniation. Patients with inadequate disc height or
small annular defects are not eligible for ACD implantation
owing to surgical access challenges and likely would not
benefit from preventative annular closure. Although pa-
tients in this study will be followed up for 5 years, long-
term outcomes with ACD are currently unknown. Finally, the
possible influence of expectation bias cannot be ruled out as
most patients and all surgeons were aware of treatment as-
signment. However, when comparing patient outcomes from
sites where the principal investigator reported a financial re-
lationship with the study sponsor versus those with no such
relationship, there were no differences in study conclu-
sions. This finding held true for the primary end point,
reherniation rates, reoperation rates, VAS scores, and ODI
scores. Further, imaging studies were evaluated by indepen-
dent radiologists.
Conclusion
In this randomized controlled trial of patients at high risk
of herniation recurrence after lumbar microdiscectomy, ad-
ditional annular closure with a bone-anchored device lowers
the risk of recurrent herniation and reoperation through 2-year
follow-up.
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